泓博医药
(301230)
| 流通市值：19.81亿 | | | 总市值：35.99亿 |
| 流通股本：7686.03万 | | | 总股本：1.40亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 391,402,290.83 | 265,763,514.46 | 130,725,745.26 | 489,717,074.89 |
| 营业收入 | 391,402,290.83 | 265,763,514.46 | 130,725,745.26 | 489,717,074.89 |
| 二、营业总成本 | 396,611,989.68 | 264,855,371.94 | 135,325,810.41 | 450,092,838.01 |
| 营业成本 | 298,418,994.94 | 202,566,520.19 | 103,778,044.13 | 338,514,627.37 |
| 税金及附加 | 1,254,150.81 | 797,962.8 | 521,749.41 | 1,241,753.94 |
| 销售费用 | 9,644,308.83 | 6,844,243.12 | 3,184,050.17 | 12,896,930.53 |
| 管理费用 | 49,076,054.68 | 31,716,228.05 | 16,112,686.45 | 60,688,102.74 |
| 研发费用 | 35,900,683.08 | 22,818,570.81 | 11,274,826.18 | 37,336,023.31 |
| 财务费用 | 2,317,797.34 | 111,846.97 | 454,454.07 | -584,599.88 |
| 其中:利息费用 | 7,046,648.79 | 4,751,248.03 | 2,410,254.65 | 5,462,237.16 |
| 其中:利息收入 | 2,635,926.16 | 1,823,420.7 | 724,215.75 | 5,526,616.74 |
| 加:公允价值变动收益 | 3,999,617.46 | 184,024.09 | 1,194,880.73 | 5,580,646.47 |
| 加:投资收益 | 3,503,429.13 | 5,327,629.02 | 1,938,566.65 | 628,463.41 |
| 资产处置收益 | - | - | - | 5,799.54 |
| 资产减值损失(新) | 2,282,890.76 | 2,692,049.53 | 3,258,818.23 | -12,093,289.1 |
| 信用减值损失(新) | -1,315,054.1 | -1,401,287.23 | -795,773.29 | -273,136.2 |
| 其他收益 | 3,172,132.72 | 2,787,493.21 | 768,289.85 | 3,971,599.62 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 6,433,317.12 | 10,498,051.14 | 1,764,717.02 | 37,444,320.62 |
| 加:营业外收入 | 156,953.35 | 123,620 | 121,610 | 26,279.31 |
| 减:营业外支出 | 125,083.32 | 52,357.53 | 28,449.52 | 707,820.16 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 6,465,187.15 | 10,569,313.61 | 1,857,877.5 | 36,762,779.77 |
| 减:所得税费用 | -8,778,418.7 | -5,407,177.55 | -1,809,783.06 | -856,469.32 |
| 六、净利润 | 15,243,605.85 | 15,976,491.16 | 3,667,660.56 | 37,619,249.09 |
| 持续经营净利润 | 15,243,605.85 | 15,976,491.16 | 3,667,660.56 | 37,619,249.09 |
| 归属于母公司股东的净利润 | 15,243,605.85 | 15,976,491.16 | 3,667,660.56 | 37,619,249.09 |
| (一)基本每股收益 | 0.11 | 0.11 | 0.03 | 0.35 |
| (二)稀释每股收益 | 0.11 | 0.11 | 0.03 | 0.35 |
| 八、其他综合收益 | -4,824.99 | -51,900.47 | - | 82,460.86 |
| 归属于母公司股东的其他综合收益 | -4,824.99 | -51,900.47 | - | 82,460.86 |
| 九、综合收益总额 | 15,238,780.86 | 15,924,590.69 | 3,667,660.56 | 37,701,709.95 |
| 归属于母公司股东的综合收益总额 | 15,238,780.86 | 15,924,590.69 | 3,667,660.56 | 37,701,709.95 |
| 公告日期 | 2024-10-28 | 2024-08-28 | 2024-04-26 | 2024-04-24 |
| 审计意见(境内) | | | | 标准无保留意见 |